Weichenthal M, Siemann U, Neuber K, Breitbart E W
Department of Dermatology, St. Georg Hospital, Hamburg, Germany.
J Cutan Pathol. 1999 May;26(5):217-21. doi: 10.1111/j.1600-0560.1999.tb01833.x.
The expression of complement regulatory antigens C3b/C4b receptor, (CD35) membrane cofactor protein (CD46), decay accelerating factor (CD55), and homologous restriction factor 20 (CD59) was determined immunohistochemically on ten primary malignant melanomas, 16 metastatic lesions, and ten melanocytic nevi. All of the melanocytic nevi and 9/10 primary melanomas showed both expression of CD46 and CD59. In one primary melanoma lacking CD46, expression of CD35 could be detected. In metastatic melanoma, 9/16 metastases were CD46+/CD59+, two were CD46-/CD59+, one CD46+/CD59-, and four CD46-/CD59-. Additionally, CD55 could be detected in two CD46+/CD59+ metastases, and CD35 in one. Expression or lack of complement regulatory antigens did not correlate with the expression of GD2, GD3, HMB-45 or S-100. In conclusion, some cases of metastatic melanoma show loss of normal expression of complement regulatory proteins. This might have implications on the immune response or the efficacy of immune therapy in malignant melanoma.
采用免疫组织化学方法测定了10例原发性恶性黑色素瘤、16个转移病灶及10个黑素细胞痣中补体调节抗原C3b/C4b受体（CD35）、膜辅因子蛋白（CD46）、衰变加速因子（CD55）和同源限制因子20（CD59）的表达情况。所有黑素细胞痣及9/10的原发性黑色素瘤均显示CD46和CD59表达。在1例缺乏CD46的原发性黑色素瘤中，可检测到CD35的表达。在转移性黑色素瘤中，9/16的转移灶为CD46+/CD59+，2个为CD46-/CD59+，1个为CD46+/CD59-，4个为CD46-/CD59-。此外，在2个CD46+/CD59+转移灶中可检测到CD55，在1个转移灶中可检测到CD35。补体调节抗原的表达或缺失与GD2、GD3、HMB-45或S-100的表达无关。总之，部分转移性黑色素瘤病例显示补体调节蛋白正常表达缺失。这可能对恶性黑色素瘤的免疫反应或免疫治疗疗效产生影响。
